You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Boehringer Ingelheim
McKesson
Medtronic
Merck

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,487,093

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,487,093 protect, and when does it expire?

Patent 8,487,093 protects RECARBRIO and is included in one NDA.

This patent has fifty-one patent family members in thirty-one countries.

Summary for Patent: 8,487,093
Title:.beta.-lactamase inhibitors
Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are .beta.-lactamase inhibitors, wherein a, X, R.sup.1 and R.sup.2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with .beta.-lactam antibiotics. In particular, the compounds can be employed with a .beta.-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to .beta.-lactam antibiotics due to the presence of the .beta.-lactamases.
Inventor(s): Blizzard; Timothy A. (Princeton, NJ), Chen; Helen (Marlboro, NJ), Gude; Candido (Staten Island, NY), Hermes; Jeffrey D. (Warren, NJ), Imbriglio; Jason (Piscataway, NJ), Kim; Seongkon (Holmdel, NJ), Wu; Jane Y. (Marlboro, NJ), Mortko; Christopher J. (Hoboken, NJ), Mangion; Ian (Cranford, NJ), Rivera; Nelo (New Milford, NJ), Ruck; Rebecca T. (Jersey City, NJ), Shevlin; Michael (Plainfield, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/812,763
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,487,093

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)   Start Trial
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)   Start Trial
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,487,093

PCT Information
PCT FiledJanuary 15, 2009PCT Application Number:PCT/US2009/031047
PCT Publication Date:July 23, 2009PCT Publication Number: WO2009/091856

International Family Members for US Patent 8,487,093

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009206119   Start Trial
Canada 2712783   Start Trial
China 101918407   Start Trial
China 102827067   Start Trial
Colombia 6331438   Start Trial
Costa Rica 11626   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.